Effect of supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of omega-3 plus vitamin E supplementation compared with the placebo on gene expression related to lipid, lipid profiles and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201601085623N67

Enrollment

Registered

2016-01-20

Start date

2015-12-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Omega-3 fatty acid plus vitamin E capsule, 1000 mg omega-3 fatty acid and 400 mg vitamin E, daily for 12 weeks orally. Intervention 2: Control group: Placebo capsul

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria Higher than 5 years of their disease Aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Unwillingness to cooperate Metabolic disorders

Design outcomes

Primary

Measure	Time frame
Gene expression of OX-LDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR-RT.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.	—

Secondary

Measure	Time frame
LDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Gene expression of Lp(a). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR-RT.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.	—

Measure

Time frame

LDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Gene expression of Lp(a). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR-RT.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026